Cardiothoracic Surgery

Compared with men, women continue to have a roughly 30-40 percent higher risk of dying following coronary artery bypass surgery, according to a large study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.

A protein commonly found at high levels in lung cancer cells controls a major immunosuppressive pathway that allows lung tumors to evade immune attack.

Dr. Sandhya K. Balaram, a leading adult cardiac surgeon in New York City, has been named chief of the Department of Cardiothoracic Surgery at NewYork-Presbyterian Brooklyn Methodist Hospital.

A multidisciplinary team of Weill Cornell Medicine researchers has received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.

A new analysis shows that a combination of two anti-platelets drugs can benefit patients after the most common type of cardiac surgery — while also increasing the risk of potentially dangerous bleeding. 

Depleting copper levels may reduce the production of energy that cancer cells need to travel and establish themselves in other parts of the body by a process referred to as metastasis.

A simple surgical technique during cardiac surgery was associated with a 56 percent reduction in the incidence of an irregular heart rhythm known as atrial fibrillation that can lead to stroke, with no added risks or side effects, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new way to counter this immunosuppressive effect.

Combining immunotherapy with targeted radiation resulted in a greater response rate than immunotherapy alone in a phase 2 clinical trial in patients with early-stage, non-small-cell lung cancer led by Weill Cornell Medicine and NewYork-Presbyterian investigators.